Healios K.K. (4593.T)
JPY 323.0
(0.94%)
JPY 323.0
(0.94%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.48 Billion JPY | -40.88% |
| 2022 | 5.26 Billion JPY | -2.88% |
| 2021 | 5.42 Billion JPY | 28.83% |
| 2020 | 4.21 Billion JPY | -1.38% |
| 2019 | 4.27 Billion JPY | -15.66% |
| 2018 | 5.06 Billion JPY | 113.4% |
| 2017 | 2.37 Billion JPY | -33.65% |
| 2016 | 3.57 Billion JPY | 211.17% |
| 2015 | 1.14 Billion JPY | 43.82% |
| 2014 | 799.06 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 679 Million JPY | -23.68% |
| 2024 Q1 | 984 Million JPY | -15.25% |
| 2023 Q4 | 1.16 Billion JPY | 54.39% |
| 2023 FY | 3.11 Billion JPY | -40.88% |
| 2023 Q2 | 754 Million JPY | -15.75% |
| 2023 Q1 | 895 Million JPY | -21.01% |
| 2023 Q3 | 752 Million JPY | -0.27% |
| 2022 Q1 | 1.43 Billion JPY | -5.52% |
| 2022 Q4 | 1.13 Billion JPY | 8.01% |
| 2022 FY | 5.26 Billion JPY | -2.88% |
| 2022 Q3 | 1.04 Billion JPY | -36.31% |
| 2022 Q2 | 1.64 Billion JPY | 14.45% |
| 2021 Q3 | 1.44 Billion JPY | 37.27% |
| 2021 FY | 5.42 Billion JPY | 28.83% |
| 2021 Q1 | 1.41 Billion JPY | 11.87% |
| 2021 Q2 | 1.04 Billion JPY | -25.81% |
| 2021 Q4 | 1.52 Billion JPY | 5.76% |
| 2020 FY | 4.21 Billion JPY | -1.38% |
| 2020 Q4 | 1.26 Billion JPY | 16.5% |
| 2020 Q3 | 1.08 Billion JPY | 17.42% |
| 2020 Q2 | 924 Million JPY | -1.39% |
| 2020 Q1 | 937 Million JPY | -24.74% |
| 2019 FY | 4.27 Billion JPY | -15.66% |
| 2019 Q2 | 985 Million JPY | -0.81% |
| 2019 Q1 | 993 Million JPY | -3.59% |
| 2019 Q3 | 1.08 Billion JPY | 9.75% |
| 2019 Q4 | 1.24 Billion JPY | 15.17% |
| 2018 Q4 | 1.03 Billion JPY | 40.71% |
| 2018 FY | 5.06 Billion JPY | 113.4% |
| 2018 Q2 | 2.74 Billion JPY | 396.93% |
| 2018 Q1 | 553 Million JPY | 0.49% |
| 2018 Q3 | 732 Million JPY | -73.36% |
| 2017 Q1 | 508.68 Million JPY | 7.78% |
| 2017 Q4 | 550.3 Million JPY | -36.18% |
| 2017 Q2 | 451.28 Million JPY | -11.28% |
| 2017 Q3 | 862.28 Million JPY | 91.07% |
| 2017 FY | 2.37 Billion JPY | -33.65% |
| 2016 Q1 | 2.13 Billion JPY | 470.32% |
| 2016 FY | 3.57 Billion JPY | 211.17% |
| 2016 Q4 | 471.94 Million JPY | 1.69% |
| 2016 Q3 | 464.1 Million JPY | -8.42% |
| 2016 Q2 | 506.75 Million JPY | -76.24% |
| 2015 Q4 | 374.03 Million JPY | 80.36% |
| 2015 Q1 | 250.09 Million JPY | 0.0% |
| 2015 Q2 | 317.68 Million JPY | 27.02% |
| 2015 Q3 | 207.37 Million JPY | -34.72% |
| 2015 FY | 1.14 Billion JPY | 43.82% |
| 2014 FY | 799.06 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -171.473% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -504.527% |
| GNI Group Ltd. | 9.32 Billion JPY | 62.595% |
| Linical Co., Ltd. | 2.7 Billion JPY | -28.9% |
| Trans Genic Inc. | 2.15 Billion JPY | -61.448% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -133.845% |
| Soiken Holdings Inc. | 3.07 Billion JPY | -13.543% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | -87.779% |
| AnGes, Inc. | 8.9 Billion JPY | 60.83% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -269.746% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 81.829% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -744.33% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -257.505% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | -35.809% |
| CanBas Co., Ltd. | 278 Million JPY | -1154.317% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -205.466% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | -91.809% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -117.426% |
| Kidswell Bio Corporation | 2.37 Billion JPY | -46.879% |
| PeptiDream Inc. | 9.68 Billion JPY | 64.004% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | -77.855% |
| Ribomic Inc. | 1.1 Billion JPY | -215.368% |
| SanBio Company Limited | 4.53 Billion JPY | 23.177% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -201.973% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -161.303% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -148.457% |
| StemRIM | 2.07 Billion JPY | -67.967% |
| CellSource Co., Ltd. | 1.96 Billion JPY | -77.591% |
| FunPep Company Limited | 313.82 Million JPY | -1011.143% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -263.983% |
| Stella Pharma Corporation | 963.98 Million JPY | -261.728% |
| TMS Co., Ltd. | 943.25 Million JPY | -269.678% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -219.922% |
| Cuorips Inc. | 598.11 Million JPY | -482.995% |
| K Pharma,Inc. | 543.94 Million JPY | -541.061% |
| Takara Bio Inc. | 23.9 Billion JPY | 85.413% |
| ReproCELL Incorporated | 1.51 Billion JPY | -130.315% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -194.513% |
| StemCell Institute Inc. | 1.16 Billion JPY | -200.055% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -129.065% |
| CellSeed Inc. | 804.93 Million JPY | -333.205% |